Technology

Pulmatrix

$1.35
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.08 (-5.23%) Today
-$0.10 (-6.90%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Pulmatrix and other stocks, options, and ETFs commission-free!

About PULM

Pulmatrix, Inc. Common Stock, also called Pulmatrix, is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA. The listed name for PULM is Pulmatrix, Inc. Common Stock.

CEO
Teofilo Raad
Employees
22
Headquarters
Lexington, Massachusetts
Founded
2015
Market Cap
48.66M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.65M
High Today
$1.54
Low Today
$1.37
Open Price
$1.47
Volume
1.28M
52 Week High
$2.06
52 Week Low
$0.90

Collections

PULM Earnings

-$0.41
-$0.27
-$0.14
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 25, Pre-Market

You May Also Like

SWK
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure